Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy

Pediatric Research
Yasuhiro TakeshimaMasafumi Matsuo

Abstract

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease that is characterized by muscle dystrophin deficiency. We report that intravenous (IV) infusion of an antisense oligonucleotide created an in-frame dystrophin mRNA from an out-of-frame DMD mutation (via exon skipping) which led to muscle dystrophin expression. A 10-year-old DMD patient possessing an out-of-frame, exon 20 deletion of the dystrophin gene received a 0.5 mg/kg IV infusion of an antisense 31-mer phosphorothioate oligonucleotide against the splicing enhancer sequence of exon 19. This antisense construct was administered at one-week intervals for 4 wk. No side effects attributable to infusion were observed. Exon 19 skipping appeared in a portion of the dystrophin mRNA in peripheral lymphocytes after the infusion. In a muscle biopsy one week after the final infusion, the novel in-frame mRNA lacking both exons 19 and 20 was identified and found to represent approximately 6% of the total reverse transcription PCR product. Dystrophin was identified histochemically in the sarcolemma of muscle cells after oligonucleotide treatment. These findings demonstrate that phosphorothioate oligonucleotides may be administered safely to children with DMD, and that a s...Continue Reading

References

Jul 27, 2001·Human Molecular Genetics·J C van DeutekomG J van Ommen
Apr 2, 2003·Human Molecular Genetics·Annemieke Aartsma-RusJudith C T van Deutekom
Jul 10, 2003·Lancet Neurology·Robert KapsaEdward Byrne
Jul 18, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Rolf A Stahel, Uwe Zangemeister-Wittke
Jul 23, 2003·Human Molecular Genetics·Bianca L GebskiStephen D Wilton
Oct 4, 2003·Nature Reviews. Genetics·Judith C T van Deutekom, Gert-Jan B van Ommen
Dec 19, 2003·American Journal of Human Genetics·Annemieke Aartsma-RusJudith C T van Deutekom
Jan 31, 2004·Annals of the New York Academy of Sciences·Jon T Holmlund
Nov 9, 2004·Pediatric Research·James G Tidball, Michelle Wehling-Henricks
Dec 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Qi Long LuTerence Partridge
Dec 22, 2004·Human Gene Therapy·Norma B RomeroMichel Fardeau
Jan 1, 2005·Current Opinion in Oncology·Asher Chanan-Khan

❮ Previous
Next ❯

Citations

Apr 22, 2008·Molecular Diagnosis & Therapy·Anthony Scimè, Michael A Rudnicki
Aug 30, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Dominic J Wells
May 11, 2011·Nature Communications·Atsushi NishidaMasafumi Matsuo
Feb 13, 2008·Nature Clinical Practice. Neurology·Leland E Lim, Thomas A Rando
Oct 3, 2007·Gene Therapy·B L AlexanderS Ylä-Herttuala
May 29, 2009·Genetic Testing and Molecular Biomarkers·Yo OkizukaMasafumi Matsuo
Mar 26, 2013·Human Gene Therapy·Taeyoung Koo, Matthew J Wood
Jan 8, 2009·Oligonucleotides·John BaumanRyszard Kole
Jul 26, 2008·Annals of Human Genetics·A NishiyamaM Matsuo
Aug 7, 2010·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Hideo Sugita, Shin'ichi Takeda
Jun 1, 2009·Bioanalysis·Guy A Tremblay, Philip R Oldfield
Mar 31, 2011·Future Medicinal Chemistry·Tsuyoshi YamamotoSatoshi Obika
Nov 1, 2013·Nucleic Acid Therapeutics·Peter JärverMichael J Gait
Oct 1, 2008·Expert Opinion on Drug Discovery·Ravinder Malik, Ipsita Roy
Jun 17, 2009·Expert Opinion on Biological Therapy·Capucine TrolletGeorge Dickson
Jun 2, 2012·Expert Opinion on Biological Therapy·Toshifumi YokotaHanna Kolski
Feb 13, 2015·Rinshō shinkeigaku = Clinical neurology·Yasuhiro Takeshima
Jan 27, 2016·Molecular Therapy. Nucleic Acids·Jean-Paul Iyombe-EngembeJacques P Tremblay
Jun 23, 2015·Brain & Development·Masafumi MatsuoHisahide Nishio
Mar 17, 2009·Biochimica Et Biophysica Acta·Chris RuszczakNick Menhart
Apr 5, 2013·Muscle & Nerve·Patryk KoniecznyJeffrey S Chamberlain
Dec 1, 2009·Biochemical and Biophysical Research Communications·Hirohide AsaiSatoshi Ueno
Feb 27, 2013·Journal of Neurogenetics·Abdul Qawee RaniZ A M H Zabidi-Hussin
Jun 9, 2015·Trends in Molecular Medicine·S D WiltonS Fletcher
Jun 21, 2011·Artificial DNA, PNA & XNA·Camilla Brolin, Takehiko Shiraishi
Sep 29, 2006·Biochimica Et Biophysica Acta·Thomas A Rando
Jun 12, 2016·Nucleic Acids Research·Mallory A Havens, Michelle L Hastings
Nov 3, 2016·Expert Opinion on Biological Therapy·S FletcherS D Wilton

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

The New England Journal of Medicine
Judith C T van DeutekomGert-Jan B Van Ommen
American Journal of Human Genetics
Annemieke Aartsma-RusJudith C T van Deutekom
Neuromuscular Disorders : NMD
Graham McCloreySteve D Wilton
Proceedings of the National Academy of Sciences of the United States of America
Qi Long LuTerence A Partridge
© 2022 Meta ULC. All rights reserved